Repeated Endocardial Mapping for Efficacy Assessment After Catheter Ablation for Ischemic Ventricular Tachycardia

Launched by UNIVERSITY MEDICAL CENTRE LJUBLJANA · Jan 26, 2023

Keywords

ClinConnect Summary

REMAP-VT is an observational study at the University Medical Centre Ljubljana that aims to learn how repeated heart mapping after catheter ablation works for people with ischemic ventricular tachycardia (VT), a fast heartbeat that starts in the heart’s lower chamber. About 20 adults with ischemic heart disease and a clear need for VT ablation will be enrolled. After the initial ablation, doctors will create a detailed map of the scar tissue and then remap it in the same procedure. About 3 months later, patients will be tested to see if sustained VT can be induced and will be remapped again. A positive outcome means there is no electrical activity in the previously treated areas and VT cannot be induced at the repeat test; a negative outcome means electrical activity returns or VT can be induced, which may indicate recurrence or failure of the procedure.

Who may join: adults aged 18–85 with ischemic cardiomyopathy, sustained VT, and an implanted or planned implantable cardioverter-defibrillator (ICD) that can record heart signals. Exclusions include nonischemic cardiomyopathy, a need for epicardial (outside-the-heart) access, serious acute organ problems, or a terminal illness with less than one year of expected survival. The study is non-randomized and follows standard care with extra heart mapping to study outcomes. Participants will undergo ablation, repeated mapping, possible extra ablation, and follow-up visits with device checks over the coming months. The trial is currently enrolling by invitation, results are not yet available, and individual patient data will not be shared.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ischemic heart disease,
• • sustained ventricular tachycardia,
• • implanted (or scheduled for implantation) cardiac electrical device with ability to record and store intracardiac electrograms
• Exclusion Criteria:
• • nonischemic cardiomyopathy,
• • need for epicardial access to the substrate for treatment of ventricular tachycardia,
• • any severe acute organ damage beyond cardiomyopathy that could potentialy omit remapping procedure after 3 months,
• • any terminal disease with expected survival of less than one year